EA199901075A1 - Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста - Google Patents
Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона ростаInfo
- Publication number
- EA199901075A1 EA199901075A1 EA199901075A EA199901075A EA199901075A1 EA 199901075 A1 EA199901075 A1 EA 199901075A1 EA 199901075 A EA199901075 A EA 199901075A EA 199901075 A EA199901075 A EA 199901075A EA 199901075 A1 EA199901075 A1 EA 199901075A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formula
- growth hormone
- secretion
- methods
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Данное изобретение относится к способам лечения резистентности к инсулину у млекопитающего, при которых указанному млекопитающему вводят эффективное количество соединения формулы Iгде переменные являются такими, как определено в описании, или его стереоизомерных смесей, диастереомерно обогащенных, диастереомерно чистых, энантиомерно обогащенных или энантиомерно чистых изомеров, или фармацевтически приемлемых солей и пролекарств. Соединения формулы (I) являются средствами, стимулирующими секрецию гормона роста, и как таковые могут применяться для увеличения уровня эндогенного гормона роста. В другом аспекте данного изобретения предложены некоторые промежуточные соединения, которые можно использовать в синтезе упомянутых выше соединений, и некоторые способы, используемые для синтеза указанных промежуточных соединений и соединений формулы (I). Кроме того, данное изобретение относится к способам, при которых человеку или другому животному вводят комбинацию функционального антагониста соматостатина, такого как α-2-адренергический агонист, и соединения формулы (I).Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5079097P | 1997-06-25 | 1997-06-25 | |
PCT/IB1998/000876 WO1998058949A1 (en) | 1997-06-25 | 1998-06-05 | Treatment of insulin resistance with growth hormone secretagogues |
Publications (2)
Publication Number | Publication Date |
---|---|
EA199901075A1 true EA199901075A1 (ru) | 2000-08-28 |
EA002089B1 EA002089B1 (ru) | 2001-12-24 |
Family
ID=21967444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199901075A EA002089B1 (ru) | 1997-06-25 | 1998-06-05 | Способ лечения резистентности к инсулину средствами, стимулирующими секрецию гормона роста |
Country Status (41)
Country | Link |
---|---|
US (3) | US6448263B1 (ru) |
EP (1) | EP1000085B1 (ru) |
JP (2) | JP2000514099A (ru) |
KR (1) | KR20010014224A (ru) |
CN (2) | CN1152049C (ru) |
AP (1) | AP1145A (ru) |
AR (1) | AR012256A1 (ru) |
AT (1) | ATE305477T1 (ru) |
AU (1) | AU747510B2 (ru) |
BG (1) | BG104008A (ru) |
BR (1) | BR9810477A (ru) |
CA (1) | CA2294464A1 (ru) |
CO (1) | CO4950621A1 (ru) |
DE (1) | DE69831745T2 (ru) |
DZ (1) | DZ2539A1 (ru) |
EA (1) | EA002089B1 (ru) |
EG (1) | EG21712A (ru) |
ES (1) | ES2248899T3 (ru) |
HK (1) | HK1028051A1 (ru) |
HN (1) | HN1998000088A (ru) |
HR (1) | HRP980361A2 (ru) |
HU (1) | HUP0001922A3 (ru) |
ID (1) | ID24345A (ru) |
IL (7) | IL154116A0 (ru) |
IN (1) | IN189724B (ru) |
IS (1) | IS5275A (ru) |
MA (1) | MA24581A1 (ru) |
NO (1) | NO996205L (ru) |
NZ (1) | NZ500655A (ru) |
OA (1) | OA11242A (ru) |
PA (1) | PA8452601A1 (ru) |
PE (1) | PE105399A1 (ru) |
PL (1) | PL337659A1 (ru) |
SK (1) | SK175699A3 (ru) |
TN (1) | TNSN98113A1 (ru) |
TR (1) | TR199903257T2 (ru) |
TW (1) | TW553943B (ru) |
UA (1) | UA64751C2 (ru) |
WO (1) | WO1998058949A1 (ru) |
YU (1) | YU70199A (ru) |
ZA (1) | ZA985546B (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA64751C2 (ru) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Translated By PlajЛЕЧЕНИЕ ИНСУЛИНОВОЙ ТОЛЕРАНТНОСТИ ВЕЩЕСТВАМИ, КОТОРЫЕ УСИЛИВАЮТ СЕКРЕЦИЮ ГОРМОНА РОСТА |
UA53716C2 (ru) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратная соль замещенного дипептида в качестве средства, стимулирующего секрецию гормона роста |
US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7828934B2 (en) * | 2004-12-21 | 2010-11-09 | Hercules Incorporated | Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems |
US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
CN105164129B (zh) | 2013-05-28 | 2018-01-19 | 拉夸里亚创药株式会社 | 多晶型物形式 |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
JP6051392B1 (ja) * | 2014-08-05 | 2016-12-27 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのセリン誘導体 |
EP3212648A1 (en) * | 2014-10-31 | 2017-09-06 | RaQualia Pharma Inc. | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
CA2147503A1 (en) | 1992-11-06 | 1994-05-26 | Judith M. Pisano | Substituted dipeptide analogs promote release of growth hormone |
RU2168512C2 (ru) | 1992-12-11 | 2001-06-10 | Мерк Энд Ко., Инк. | Спиропиперидины, способы их получения (варианты) |
EP0739204A4 (en) | 1993-11-09 | 2000-03-15 | Merck & Co Inc | PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
PL327227A1 (en) | 1995-12-22 | 1998-12-07 | Novo Nordisk As | Compounds exhibiting growth hormone liberating properties |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
UA53716C2 (ru) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратная соль замещенного дипептида в качестве средства, стимулирующего секрецию гормона роста |
AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA64751C2 (ru) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Translated By PlajЛЕЧЕНИЕ ИНСУЛИНОВОЙ ТОЛЕРАНТНОСТИ ВЕЩЕСТВАМИ, КОТОРЫЕ УСИЛИВАЮТ СЕКРЕЦИЮ ГОРМОНА РОСТА |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/ru unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Application Discontinuation
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko active Search and Examination
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2000
- 2000-11-23 HK HK00107485A patent/HK1028051A1/xx not_active IP Right Cessation
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199901075A1 (ru) | Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста | |
EP1862458A3 (en) | Therapeutic agents useful for treating pain | |
EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
EA200200194A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
BR0316305A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit | |
EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
EA200100284A1 (ru) | Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени | |
ATE181329T1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
EA200401301A1 (ru) | Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора | |
RU2000123169A (ru) | Бензотиадиазолы и их производные | |
CY1119257T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda) | |
ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
EA200000693A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
EA200100140A1 (ru) | Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами | |
EA200500045A1 (ru) | Новые соединения, их применение и получение | |
KR910004665A (ko) | 사이클릭 뉴로키닌 a 길항제 | |
EA200400692A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
BR9911756A (pt) | Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |